FT218 FDA Approval Status
Last updated by Judith Stewart, BPharm on March 3, 2021.
FDA Approved: No
Brand name: FT218
Generic name: sodium oxybate
Company: Avadel Pharmaceuticals plc
Treatment for: Narcolepsy
FT218 (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Development timeline for FT218
| Date | Article |
|---|---|
| Mar 1, 2021 | Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.